METASTATIC BREAST CARCINOMA

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This early-phase trial tests a combination of two drugs, cyclophosphamide and veliparib, in people with HER2-negative breast cancer that has spread or cannot be surgically removed. The main goal is to find the safest dose and check for side effects. Up to 35 participants will rec…

This phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard hormone therapy (letrozole or fulvestrant) and the targeted drug palbociclib can shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor-positive bre…

This early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study looks at whether regular blood tests can detect changes in stage IV breast cancer during treatment. Researchers will collect blood samples from 150 adults with metastatic breast cancer and analyze them for tumor DNA. The goal is to see if these tests can spot when the …

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study collects blood and tissue samples from 300 people with breast cancer that has spread or come back. The goal is to create a large research registry that helps doctors understand why tumors spread and why people respond differently to treatments. Participants provide sam…

This study tests whether watching a short video can improve understanding of tumor genomic testing in 243 adults with metastatic cancer. Participants watch the video and then answer questions to measure their knowledge. The goal is to see if this simple tool helps patients better…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…